ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Erbitux (cetuximab) by Year
Erbitux (cetuximab) — Outside U.S. revenue ($M) [legacy] ($M)
Eli Lilly Erbitux (cetuximab): $65.3M in FY2024, down 3.4% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2024
65.3
Period ended Dec 31, 2024
Change on a year earlier
-3.4%
67.6 in FY2023
History
9 years
Since FY2016
Sources
7
Documents cited below
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-19) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Erbitux (cetuximab) — Outside U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 65.3 | -3.4% | Form 10-K (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 67.6 | +1.8% | Form 10-K (filed 2025-02-19) ↗ |
| FY2022 | Dec 31, 2022 | 66.4 | 0.0% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 66.4 | +17.9% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 56.3 | +1.6% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 55.4 | -46.6% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 104 | -0.4% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 104 | -1.6% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 106 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Erbitux (cetuximab) ($M), annual FY2016–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-erbitux-nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.